San Francisco-based Amae Health has just secured a hefty $25 million in Series B funding, pushing its total raised past $50 million since its 2022 inception. This fresh capital isn't just pocket change; it's the fuel for a major nationwide expansion, aiming to redefine how serious mental illnesses (SMIs) are treated.
The company, which focuses on integrated, psychiatry-led outpatient care for adults with SMIs, is doubling down on its AI capabilities. CEO Stas Sokolin told Behavioral Health Business that Amae is entering a "major growth phase," with plans to significantly increase its clinic footprint across the U.S. This isn't just about more brick-and-mortar locations; it's about building a "nationwide precision care ecosystem" that blends in-person treatment with cutting-edge digital monitoring and predictive analytics.
AI Takes Center Stage in Mental Health
Amae's existing AI platform already crunches data from wearables, patient records, and measurement-based assessments to inform coordinated care. With the Series B injection, led by Altos Ventures alongside Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital, and 8VC, Amae is rolling out three new AI features. These include a unified data dashboard, an AI clinical assistant designed to flag changes and monitor patient status, and advanced symptomology phenotyping for hyper-personalized treatment.
This move signals a clear shift towards more data-driven, precision-based mental healthcare, a critical evolution for conditions often characterized by complex, fluctuating symptoms. By integrating wearable tech across its member base, Amae aims to strengthen longitudinal data collection, enabling better relapse prevention and continuous refinement of care delivery. The company also plans to deepen its partnerships with academic medical centers like Stanford Health Care and Massachusetts General Hospital, further bridging research with real-world clinical application.
